<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>江苏金殳 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-02T16:27:40+08:00</updated>
  <subtitle>致力于仿制药、创新药的研发，核心团队近十几年投身于药理毒理、药学和临床注册研究。公司全体员工以改善人类健康问题为己任，努力做出高质量、价格低、疗效好和安全性高的药品，创造制药企业的社会价值，实现制药人的人生价值。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>疫情与新规背景下对基于风险的监查的认识</title>
    <updated>2020-12-02T13:59:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/6bkOm1m1rC6dbpZZUpZMgg</id>
    <link href="https://mp.weixin.qq.com/s/6bkOm1m1rC6dbpZZUpZMgg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《药品附条件批准上市技术指导原则（试行）》的通知</title>
    <updated>2020-12-02T13:59:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/_FrnnEPthEwiJxpL2pcYmg</id>
    <link href="https://mp.weixin.qq.com/s/_FrnnEPthEwiJxpL2pcYmg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《疫苗临床试验抗体分析方法研究技术指导原则（征求意见稿）》的通知</title>
    <updated>2020-12-02T13:59:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/cuniiJnpkI4XOMUGmrFS6A</id>
    <link href="https://mp.weixin.qq.com/s/cuniiJnpkI4XOMUGmrFS6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《GnRH激动剂用于晚期前列腺癌临床试验设计指导原则》的通告</title>
    <updated>2020-12-02T13:59:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/KjVj-BKXORqInbEUCbH5TA</id>
    <link href="https://mp.weixin.qq.com/s/KjVj-BKXORqInbEUCbH5TA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《晚期肝细胞癌临床试验终点技术指导原则》的通告</title>
    <updated>2020-12-02T13:59:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/fHYVQjTFLl245cnbrb7GPg</id>
    <link href="https://mp.weixin.qq.com/s/fHYVQjTFLl245cnbrb7GPg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>特殊制剂——口腔膜剂简介</title>
    <updated>2020-11-23T10:04:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/I-sAP_c8zXxCAkTmOOXq7Q</id>
    <link href="https://mp.weixin.qq.com/s/I-sAP_c8zXxCAkTmOOXq7Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>感恩节|一路相伴，感恩有你</title>
    <updated>2020-11-23T10:04:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/Uv51x0eEi0aVlzUsQ3dwHw</id>
    <link href="https://mp.weixin.qq.com/s/Uv51x0eEi0aVlzUsQ3dwHw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《中药注册受理审查指南（试行）》</title>
    <updated>2020-11-23T10:04:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/ixNW8i9kmy84L79bFBluTQ</id>
    <link href="https://mp.weixin.qq.com/s/ixNW8i9kmy84L79bFBluTQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《中药新药研究各阶段药学研究技术指导原则（试行）》</title>
    <updated>2020-11-23T10:04:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/6gee4ccR0kbgFUwx_au1JA</id>
    <link href="https://mp.weixin.qq.com/s/6gee4ccR0kbgFUwx_au1JA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《中药均一化研究技术指导原则（试行）》</title>
    <updated>2020-11-23T10:04:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/6vBmfWwWo7K0qbgDaZoL2w</id>
    <link href="https://mp.weixin.qq.com/s/6vBmfWwWo7K0qbgDaZoL2w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品研制机构如何做好MAH质量保证体系？</title>
    <updated>2020-11-16T09:00:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/iP_BHfTu-hMEKreR-g_BqQ</id>
    <link href="https://mp.weixin.qq.com/s/iP_BHfTu-hMEKreR-g_BqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《药品上市许可持有人检查要点（征求意见稿）》</title>
    <updated>2020-11-16T09:00:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/65uXXwaOnlWTAICLi-YTvA</id>
    <link href="https://mp.weixin.qq.com/s/65uXXwaOnlWTAICLi-YTvA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《药物警戒委托协议撰写指导原则（试行）》</title>
    <updated>2020-11-16T09:00:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/-e5pQtqPNopG2Pv_vBNbew</id>
    <link href="https://mp.weixin.qq.com/s/-e5pQtqPNopG2Pv_vBNbew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规分享||《药品委托生产质量协议指南（2020年版）》</title>
    <updated>2020-11-16T09:00:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/xDi1l3USiNGJThG0tnCKBA</id>
    <link href="https://mp.weixin.qq.com/s/xDi1l3USiNGJThG0tnCKBA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>乳状注射液的临床研究思路</title>
    <updated>2020-11-09T09:30:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/TX7j47OCyjzHwiqKvtWtwg</id>
    <link href="https://mp.weixin.qq.com/s/TX7j47OCyjzHwiqKvtWtwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NMPA发布《化学药品注射剂仿制药质量和疗效一致性评价技术要求》《已上市化学药品注射剂仿制药质量和疗效一致性评价申报资料要求》</title>
    <updated>2020-11-09T09:30:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/XWcChRPXX0cAXD1SoreE6g</id>
    <link href="https://mp.weixin.qq.com/s/XWcChRPXX0cAXD1SoreE6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《化学药品注射剂仿制药（特殊注射剂）质量和疗效评价技术要求（征求意见稿）》的通知</title>
    <updated>2020-11-09T09:30:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/kbwhwu5cIukRVlewHRRdkA</id>
    <link href="https://mp.weixin.qq.com/s/kbwhwu5cIukRVlewHRRdkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《盐酸多柔比星脂质体注射液仿制药研究技术指导原则》和《注射用紫杉醇（白蛋白结合型）仿制药研究技术指导原则》</title>
    <updated>2020-11-09T09:30:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/OlrLbGSDHmKPatxXiPNsMA</id>
    <link href="https://mp.weixin.qq.com/s/OlrLbGSDHmKPatxXiPNsMA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布关于《氟维司群注射液仿制药研究技术指导原则》征求意见稿的通知</title>
    <updated>2020-11-09T09:30:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/FBSnan5llRdkiqMBRnbL0g</id>
    <link href="https://mp.weixin.qq.com/s/FBSnan5llRdkiqMBRnbL0g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>研究中心筛选访视（二） 可行性调研</title>
    <updated>2020-11-02T09:16:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/NrYwnyGY2Jpp8v3raDbPUg</id>
    <link href="https://mp.weixin.qq.com/s/NrYwnyGY2Jpp8v3raDbPUg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>